Skip to content
Stock · yahoo

Windward Bio Group AG

WWB

$24.29
▲ 0.28 (1.15%)
polled

New listing · first traded Nov 13, 2026 on Nasdaq · source: SEC EDGAR

Below: live stock price for Windward Bio Group AG (WWB), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Windward Bio Group AG (WWB) is a Healthcare company based in Switzerland. Operating in Biotechnology, it employs about 33 people. Over the past year WWB traded between 18.35 and 33.99 USD.

Day
+1.15%
+0.28
Week
-14.79%
-4.22
Month
—
Year
—
Prev close
$24.01
Volume (24h)
$3.85M
Market cap
$1.41B
Currency
USD

Scoreas of Nov 21, 2026

54/ 100 · Mixed

Coverage: 6/7
  • Value88
  • Quality13
  • Momentum23
  • Growth—
  • Risk100
  • Dividend0
  • Liquidity100

Composite of public market data. Informational only — not investment advice.

Trend projection

Not enough history to project a trend.

Interpretation

The composite score is in the mixed range. Strength: risk profile with weakness: dividend.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

  • Value
    88/100

    Value looks strong — driven by P/B (1.42).

    P/B:1.42
  • Quality
    13/100

    Quality looks fragile — driven by Profit margin (0.00%).

    Profit margin:0.00%Gross margin:0.00%
  • Momentum
    23/100

    Momentum looks fragile — driven by 52w change (-14.77%).

    52w change:-14.77%
  • Risk
    100/100

    Risk looks strong — driven by Debt / equity (0.18).

    Debt / equity:0.18
  • Dividend
    0/100

    Dividend looks fragile — driven by Dividend yield (0.00%).

    Dividend yield:0.00%
  • Liquidity
    100/100

    Liquidity looks strong — driven by Current ratio (8.57).

    Current ratio:8.57Quick ratio:8.49

Derived from public market data — informational, not investment advice.

Pivot points

Daily, from the November 20 session's high, low and close

High 26.20 · Low 22.47 · Close 24.29

LevelClassicFibonacciCamarilla
R329.9028.0525.31
R228.0526.6224.97
R126.1725.7424.63
Pivot24.3224.3224.32
S122.4422.8923.94
S220.5922.0123.60
S318.7120.5923.26

Pivot points are reference levels computed with standard formulas from the previous session's range. They are not a forecast and not a buy or sell signal.

Weekly and monthly pivots, Woodie and DeMark: pivot point calculator →

Historical data

Daily prices for the latest sessions, newest first

DateCloseOpenHighLowVolumeChange %
Nov 20, 202624.2924.4926.2022.473.85M+1.15%
Nov 19, 202624.0122.0125.0021.123.99M+6.05%
Nov 18, 202622.6425.5129.9521.0111.73M-12.11%
Nov 17, 202625.7629.6729.6721.386.34M-14.25%
Nov 16, 202630.0425.0032.0022.507.14M+5.40%

Financials

52w high
$33.99
52w low
$18.35
52w change
-14.77%
Day high
$26.20
Day low
$22.47
Price / Book
1.42
Enterprise value
1.22B
EV / EBITDA
-16.74
EPS (TTM)
-$1.18
Dividend yield
0.00%
EBITDA
-73.09M
Total cash
186.47M
Total debt
474K
Debt / Equity
0.18
Current ratio
8.57
Quick ratio
8.49
Profit margin
0.00%
Gross margin
0.00%
Shares outstanding
58.04M
Float
14.69M
Sector: HealthcareIndustry: BiotechnologyHQ: SwitzerlandEmployees: 33windwardbio.com

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.

Analyst & Risk

Consensus

Analysts' consensus via Yahoo Finance — not investment advice.

No consensus available.
Analyst price target
—
Mean target · ? analysts
52-week change
-14.77%
Debt / Equity
0.18
low leverage
Current ratio
8.57
Quick ratio
8.49
EV / EBITDA
-16.74
EBITDA
-73.09M
Total cash
186.47M
Total debt
474K
Insider holdings
13.71%
Institutional
43.62%

Analyst estimates

Consensus of research analysts' forecasts, compiled by Yahoo Finance · as of Nov 21, 2026

Estimates by period
PeriodEPS estimateEPS vs a year earlierRevenue estimateRevenue vs a year earlier
Current quarter——0range 0 – 00 analysts—
Next quarter——0range 0 – 00 analysts—
Current fiscal year——0range 0 – 00 analysts—
Next fiscal year——0range 0 – 00 analysts—

Recent news

Related

Other assets in this category.

Learn the terms

Live discussion

Sign in to join the discussion.

  • Loading…